Oncology
Laboratory Investigation
Establishment and Characterization of an Ovarian Yolk Sac Tumor Cell Line Reveals Possible Involvement of Nkx2.5 in Tumor DevelopmentShibata K. · Kajiyama H. · Yamamoto E. · Terauchi M. · Ino K. · Nawa A. · Kikkawa F.Department of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Nagoya, Japan
|
|
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
Article / Publication Details
Received: November 22, 2007
Accepted: January 29, 2008
Published online: June 12, 2008
Issue release date: June 2008
Number of Print Pages: 8
Number of Figures: 5
Number of Tables: 0
ISSN: 0030-2414 (Print)
eISSN: 1423-0232 (Online)
For additional information: https://www.karger.com/OCL
Abstract
Objective: Ovarian yolk sac tumor (YST) is rare and highly malignant. Up to the present, there have been no cell lines of human ovarian YST constructed and, therefore, no studies on their cell function. The purpose of this study was to establish a human ovarian YST cell line to be able to identify a target for novel molecular-based therapy. Methods: A 28-year-old woman underwent right salpingo-oophorectomy for right ovarian YST. YST cell lines (NOY1 and NOY2) were established from surgical specimens, and NOY1 cells were characterized. We also transfected them with small interfering RNA (siRNA) oligonucleotides specific for human Nkx2.5 and investigated cell proliferation compared to control siRNA-transfected cells. Results: The cell lines were successfully maintained both in culture and in nude mice. Histological examination showed that xenografted tumors were composed of cells in solid and glandular patterns of YST. These cells were positively immunostained for AFP. Nkx2.5 siRNA-transfected NOY1 cell viability decreased by 50% compared to that of control-siRNA-transfected cells. Conclusions: This is the first report of a cell line established from human YST. Analysis of this new cell line suggested that Nkx2.5 can be a new molecular target in the treatment of ovarian YST.
© 2008 S. Karger AG, Basel
Related Articles:
References
- Quirk JT, Natarajan N: Ovarian cancer incidence in the United States, 1992–1999. Gynecol Oncol 2005;97:519–523.
-
Gershenson DM: Update on malignant ovarian germ cell tumors. Cancer 1993;71 (4 suppl):1581–1590.
- Willemse PHB, Aalders JG, Bouma J, et al: Long-term survival after vinblastine, bleomycin, and cisplatin treatment in patients with germ cell tumors in the ovary: an update. Gynecol Oncol 1987;28:268–277.
- Lai CH, Chang TC, Hsueh S, et al: Outcome and prognostic factors in ovarian germ cell malignancies. Gynecol Oncol 2005;96:784–791.
- Billmire D, Vinocur C, Rescrla F, et al: Outcome and staging evaluation in malignant germ cell tumors of the ovary in children and adolescents: An Intergroup Study. J Pediatr Surg 2004;39:424–429.
- Zanetta G, Bonazzi C, Cantu M, et al: Survival and reproductive function after treatment of malignant germ cell ovarian tumors. J Clin Oncol 2001;19:1015–1020.
- Zanagnolo V, Sartori E, Galleri G, et al: Clinical review of 55 cases of malignant ovarian germ cell tumors. Eur J Gynaecol Oncol 2004;25:315–320.
- Williams S, Blessing JA, Liao SY, et al: Adjuvant therapy of ovarian germ cell tumors with cisplatin, etoposide, and bleomycin. J Clin Oncol 1994;12:701–706.
- Skof E, Grasic Kuhar C, Cerar O, et al: Survival and fertility of patients with malignant ovarian germ cell tumors. Eur J Gynaecol Oncol 2004;25:702–706.
- Murgaesu N, Schmid P, Dancey G, et al: Malignant ovarian germ cell tumors: identification of novel prognostic markers and long-term outcome after multimodality treatment. J Clin Oncol 2006;24:4862–4866.
-
Nichols CR: Ifosfamide in the treatment of germ cell tumors. Semin Oncol 1996;23(3 suppl 6):65–73.
- Motzer RJ, Bajorin DF, Schwartz LH, et al: Phase II trial of paclitaxel shows antitumor activity in patients with previously treated germ cell tumors. J Clin Oncol 1994;12:2277–2283.
- Einhorn LH, Stender MJ, Williams SD: Phase II trial of gemcitabine in refractory germ cell tumors. J Clin Oncol 1999;17:509–511.
-
Maas K, Daikeler T, Kanz L, Bokemeyer C: Activity of gemcitabine in platinum resistant ovarian germ cell cancer. Eur J Cancer 1996;32:1437–1438.
External Resources
- Mitchell PL, Al-Nasiri N, A’Hern R, et al: Treatment of nondysgerminomatous ovarian germ cell tumors. Cancer 1999;85:2232–2244.
- Mayordomo JI, Paz-Ares L, Rivera F, et al: Ovarian and extragonadal malignant germ-cell tumors in females: a single-institution experience with 43 patients. Ann Oncol 1994;5:225–231.
- Gorog D, Regoly-Merei J, Paku S, et al: Alpha-fetoprotein expression is a potential prognostic marker in hepatocellular carcinoma. World J Gastroenterol 2005;11:5015–5018.
- Komuro I, Izumo S: Csx: a murine homeobox-containing gene specifically expressed in the developing heart. Proc Natl Acad Sci USA 1993;90:8145–8149.
- Chen CY, Schwartz RJ: Identification of novel DNA binding targets and regulatory domains of a murine tinman homeodomain factor, nkx-2.5. J Biol Chem 1995;270:15628–15633.
- Aperqis GA, Crawford N, Ghosh D, et al: A novel nk-2 related transcription factor associated with human fetal liver and hepatocellular carcinoma. J Biol Chem 1998;273:2917–2925.
- Kajiyama Y, Tian J, Locker J: Regulation of alpha-fetoprotein expression by Nkx2.8. Mol Cell Biol 2002;22:6122–6130.
- Suzuki Y, Shibata K, Kikkawa F, et al: Possible role of Placental Leucine Aminopeptidase in the antiproliferative effect of oxytocin in human endometrial adenocarcinoma. Clin Cancer Res 2003;9:1528–1534.
- Motzer RJ, Sheinfeld J, Mazumdar M, et al: Paclitaxel, ifosfamide, and cisplatin second-line therapy for patients with relapsed testicular germ cell cancer. J Clin Oncol 2000;18:2413–2418.
- Roggia C, Ukena C, Bohm M, Kilter H: Hepatocyte growth factor (HGF) enhances cardiac commitment of differentiating embryonic stem cells by activating PI3 kinase. Exp Cell Res 2007;313:921–930.
- Liu H, Harris TM, Kim HH, Childs G: Cardiac myocyte differentiation: the Nkx2.5 and Cripto target genes in P19 clone 6 cells. Funct Integr Genomics 2005;5:218–239.
- Nagel S, Kaufmann M, Drexler HG, MacLeod RA: The cardiac homeobox gene NKX2-5 is deregulated by juxtaposition with BCL11B in pediatric T-ALL cell lines via a novel t(5;14)(q35.1;q32.2). Cancer Res 2003;63:5329–5334.
- Kwabi-Addo B, Chung W, Shen L, et al: Age-related DNA methylation changes in normal human prostate tissues. Clin Cancer Res 2007;13:3796–3802.
Article / Publication Details
Received: November 22, 2007
Accepted: January 29, 2008
Published online: June 12, 2008
Issue release date: June 2008
Number of Print Pages: 8
Number of Figures: 5
Number of Tables: 0
ISSN: 0030-2414 (Print)
eISSN: 1423-0232 (Online)
For additional information: https://www.karger.com/OCL
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Get Permission
PubMed ID
